Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.
about
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects.Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches.A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolguThe role of exercise-induced myokines in regulating metabolism.WNT-mediated Modulation of Bone Metabolism: Implications for WNT Targeting to Treat Extraskeletal Disorders.Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
P2860
Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@en
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@nl
type
label
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@en
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@nl
prefLabel
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@en
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@nl
P2093
P2860
P356
P1476
Translational Pharmacokinetic/ ...... tibody for Muscular Dystrophy.
@en
P2093
P2860
P304
P356
10.1111/CTS.12420
P407
P577
2016-10-04T00:00:00Z